OPTIBIOTIX HLTH PLC LS-02
OptiBiotix Health Plc, a life sciences company, engages in the discovery and development of microbiome modulation products in the United Kingdom, the United States, India, China, and internationally. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that can impact human physiology and derive potential… Read more
OPTIBIOTIX HLTH PLC LS-02 (OB3) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, OPTIBIOTIX HLTH PLC LS-02 (OB3) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
OPTIBIOTIX HLTH PLC LS-02 - Net Assets Trend (None–None)
This chart illustrates how OPTIBIOTIX HLTH PLC LS-02's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for OPTIBIOTIX HLTH PLC LS-02 (None–None)
The table below shows the annual net assets of OPTIBIOTIX HLTH PLC LS-02 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to OPTIBIOTIX HLTH PLC LS-02's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
OPTIBIOTIX HLTH PLC LS-02 Competitors by Market Cap
The table below lists competitors of OPTIBIOTIX HLTH PLC LS-02 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BIOSYNEX INH. EO-10
F:0DL
|
$6.77 Million |
|
Xplus SA
WAR:XPL
|
$6.77 Million |
|
Leon Fuat Bhd
KLSE:5232
|
$6.77 Million |
|
Purple Biotech
NASDAQ:PPBT
|
$6.77 Million |
|
Sidiz Inc
KO:134790
|
$6.76 Million |
|
AroCell AB
ST:AROC
|
$6.76 Million |
|
CYVIZ AS NK 110
F:8P9
|
$6.76 Million |
|
Creative Global Technology Holdings Limited Ordinary Shares
BATS:CGTL
|
$6.76 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in OPTIBIOTIX HLTH PLC LS-02's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares OPTIBIOTIX HLTH PLC LS-02's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently OPTIBIOTIX HLTH PLC LS-02 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares OPTIBIOTIX HLTH PLC LS-02's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| OPTIBIOTIX HLTH PLC LS-02 (OB3) | €- | N/A | N/A | $6.76 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |